|

Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

RECRUITINGPhase 2Sponsored by Royal Marsden NHS Foundation Trust
Actively Recruiting
PhasePhase 2
SponsorRoyal Marsden NHS Foundation Trust
Started2025-03-11
Est. completion2025-12-31
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06560905

Summary

This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.

Eligibility

Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

* Males ≥18 years of age
* Biopsy proven first and recurrent metastatic melanoma with palpable nodal disease who have undergone a staging FDG PET-CT scan as part of routine clinical care and are scheduled for surgery for resection of the primary site

Exclusion Criteria:

* Patients unable to give voluntary written informed consent to participate in this study
* Patients not willing to complete all the study assessments
* Patients who are females
* Patients who are taking androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists.
* Patients who have or have previously been diagnosed with prostate cancer
* Patients who have had Lu-177 PSMA therapy or barium studies within a period of 10 days prior to undergoing PSMA PET-CT scanning
* Patients not fluent in English

Conditions2

CancerMalignant Melanoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.